INTRODUCTION: Neurocognitive dysfunction is a major symptom feature of schizophrenia and bipolar disorder. A prognostic relationship between cognition and community outcomes is well-documented in schizophrenia and increasingly recognized in bipolar disorder. However, specific associations among neurocognition, diagnosis, state symptomatology, and community functioning are unclear, and few studies have compared these relationships among patients with affective and non-affective psychoses in the same study. We examined neurocognitive, clinical, and community functioning in a cross-diagnostic sample of patients with psychotic disorders over a 6-month follow-up interval. METHOD: Neurocognitive, clinical and community functioning were assessed in participants with schizophrenia (n=13), schizoaffective disorder (n=17), or bipolar disorder with psychosis (n=18), and healthy controls (n=18) at baseline and 6months later. RESULTS: Neurocognitive functioning was impaired in all diagnostic groups and, despite reductions in primary symptoms, did not recover on most measures over the follow-up period. Neurocognitive impairment was not associated with diagnosis or clinical improvement. Several neurocognitive scores at baseline (but not diagnosis or clinical baseline or follow-up scores) predicted community functioning at follow-up. DISCUSSION: In one of the few studies to longitudinally examine neurocognition in association with clinical and outcomes variables in a cross diagnostic sample of psychotic disorders patients, neurocognitive deficits were pronounced across diagnoses and did not recover on most measures despite significant reductions in clinical symptoms. Baseline neurocognitive functioning was the only significant predictor of patients' community functioning six months later. Efforts to recognize and address cognitive deficits, an approach that has shown promise in schizophrenia, should be extended to all patients with psychosis.
INTRODUCTION:Neurocognitive dysfunction is a major symptom feature of schizophrenia and bipolar disorder. A prognostic relationship between cognition and community outcomes is well-documented in schizophrenia and increasingly recognized in bipolar disorder. However, specific associations among neurocognition, diagnosis, state symptomatology, and community functioning are unclear, and few studies have compared these relationships among patients with affective and non-affective psychoses in the same study. We examined neurocognitive, clinical, and community functioning in a cross-diagnostic sample of patients with psychotic disorders over a 6-month follow-up interval. METHOD: Neurocognitive, clinical and community functioning were assessed in participants with schizophrenia (n=13), schizoaffective disorder (n=17), or bipolar disorder with psychosis (n=18), and healthy controls (n=18) at baseline and 6months later. RESULTS: Neurocognitive functioning was impaired in all diagnostic groups and, despite reductions in primary symptoms, did not recover on most measures over the follow-up period. Neurocognitive impairment was not associated with diagnosis or clinical improvement. Several neurocognitive scores at baseline (but not diagnosis or clinical baseline or follow-up scores) predicted community functioning at follow-up. DISCUSSION: In one of the few studies to longitudinally examine neurocognition in association with clinical and outcomes variables in a cross diagnostic sample of psychotic disorderspatients, neurocognitive deficits were pronounced across diagnoses and did not recover on most measures despite significant reductions in clinical symptoms. Baseline neurocognitive functioning was the only significant predictor of patients' community functioning six months later. Efforts to recognize and address cognitive deficits, an approach that has shown promise in schizophrenia, should be extended to all patients with psychosis.
Authors: Colin A Depp; David J Moore; David Sitzer; Barton W Palmer; Lisa T Eyler; Scott Roesch; Barry D Lebowitz; Dilip V Jeste Journal: J Affect Disord Date: 2007-01-16 Impact factor: 4.839
Authors: Christopher R Bowie; Colin Depp; John A McGrath; Paula Wolyniec; Brent T Mausbach; Mary H Thornquist; James Luke; Thomas L Patterson; Philip D Harvey; Ann E Pulver Journal: Am J Psychiatry Date: 2010-05-17 Impact factor: 18.112
Authors: K D Denicoff; S O Ali; A F Mirsky; E E Smith-Jackson; G S Leverich; C C Duncan; E G Connell; R M Post Journal: J Affect Disord Date: 1999-11 Impact factor: 4.839
Authors: Carmen Simonsen; Kjetil Sundet; Anja Vaskinn; Astrid B Birkenaes; John A Engh; Ann Faerden; Halldóra Jónsdóttir; Petter Andreas Ringen; Stein Opjordsmoen; Ingrid Melle; Svein Friis; Ole A Andreassen Journal: Schizophr Bull Date: 2009-05-14 Impact factor: 9.306
Authors: Abraham Reichenberg; Philip D Harvey; Christopher R Bowie; Ramin Mojtabai; Jonathan Rabinowitz; Robert K Heaton; Evelyn Bromet Journal: Schizophr Bull Date: 2008-05-20 Impact factor: 9.306
Authors: Charity J Morgan; Michael J Coleman; Ayse Ulgen; Lenore Boling; Jonathan O Cole; Frederick V Johnson; Jan Lerbinger; J Alexander Bodkin; Philip S Holzman; Deborah L Levy Journal: Schizophr Bull Date: 2017-05-01 Impact factor: 9.306
Authors: Kathryn E Lewandowski; Julie M McCarthy; Dost Öngür; Lesley A Norris; Geoffrey Z Liu; Richard J Juelich; Justin T Baker Journal: Schizophr Res Date: 2018-08-17 Impact factor: 4.939
Authors: David Kimhy; Julia Vakhrusheva; Matthew N Bartels; Hilary F Armstrong; Jacob S Ballon; Samira Khan; Rachel W Chang; Marie C Hansen; Lindsey Ayanruoh; Amanda Lister; Eero Castrén; Edward E Smith; Richard P Sloan Journal: Schizophr Bull Date: 2015-03-23 Impact factor: 9.306
Authors: Josephine Mollon; Anthony S David; Stanley Zammit; Glyn Lewis; Abraham Reichenberg Journal: JAMA Psychiatry Date: 2018-03-01 Impact factor: 21.596
Authors: Kathryn Eve Lewandowski; Sarah H Sperry; Dost Ongur; Bruce M Cohen; Lesley A Norris; Matcheri S Keshavan Journal: Trials Date: 2016-03-12 Impact factor: 2.279